Q2 EPS Forecast for Alto Neuroscience Lowered by Analyst

Key Points

• HC Wainwright lowered its Q2 2026 EPS estimate for Alto Neuroscience to ($0.75) from ($0.67), reflecting a softer near-term outlook for the biotech company.
• The firm also cut earnings estimates across multiple future periods, including FY2026 through FY2030, suggesting losses could persist longer than previously expected.
• Despite the lower forecasts, HC Wainwright kept a Buy rating and a $50 price target on Alto Neuroscience, while the stock recently traded at $20.24 after the company reported a wider-than-expected quarterly loss.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at HC Wainwright cut their Q2 2026 EPS estimates for Alto Neuroscience in a report released on Wednesday, May 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.75) for the quarter, down from their previous estimate of ($0.67). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.98) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.09) EPS, Q3 2027 earnings at ($1.15) EPS, Q4 2027 earnings at ($1.11) EPS, FY2027 earnings at ($4.39) EPS, FY2028 earnings at ($4.81) EPS, FY2029 earnings at ($3.50) EPS and FY2030 earnings at ($1.53) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24).

Other analysts have also recently issued reports about the stock. Wolfe Research began coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an "outperform" rating for the company. Jefferies Financial Group reiterated a "buy" rating and issued a $35.00 price target on shares of Alto Neuroscience in a research note on Monday, March 16th. JonesTrading cut their price target on Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating for the company in a research note on Thursday, April 2nd. Weiss Ratings upgraded Alto Neuroscience from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, May 1st. Finally, Chardan Capital reiterated a "buy" rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $35.25.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $20.24 on Friday. The firm has a fifty day moving average price of $23.04 and a 200-day moving average price of $19.07. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The stock has a market cap of $710.22 million, a PE ratio of -8.36 and a beta of 1.62. Alto Neuroscience has a 1 year low of $2.15 and a 1 year high of $28.44.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of ANRO. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the first quarter valued at $52,000. Torren Management LLC purchased a new position in Alto Neuroscience during the fourth quarter valued at $62,000. Invesco Ltd. purchased a new position in Alto Neuroscience during the first quarter valued at $67,000. Vanguard Personalized Indexing Management LLC grew its stake in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company's stock valued at $69,000 after acquiring an additional 2,055 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company's stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $50 price target on Alto Neuroscience, signaling continued upside confidence despite the earnings cuts.
• Positive Sentiment: Alto added Andrew Miller, Ph.D. to its Board of Directors, a move that may be viewed as strengthening governance and strategic expertise. Article Title
• Neutral Sentiment: The company expanded its board, which is a routine governance update, but could support investor confidence over time. Article Title
• Negative Sentiment: HC Wainwright lowered its EPS estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026, FY2027, FY2028, FY2029, and FY2030, reinforcing the view that losses may persist longer than previously expected.
• Negative Sentiment: The steepest revisions were to longer-term earnings, including FY2027 and FY2028, which can weigh on sentiment if investors were expecting a faster path to profitability.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.